ABBV-295_Dosage, benefits & legal status
Also known as ABBV295
The amylin entry where monthly dosing, not the size of the number, is the point.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is ABBV-295?
Plain language first. The technical label stays, but it never stands alone.Overview
Amylin is the other appetite hormone, and this site already carries ten drugs built on it. What marks this one out is not how much weight it took off but how rarely it has to be injected. A half-life of ten to twelve days meant that in early testing a single monthly injection produced about as much weight loss over three months as the weekly doses did. Read the figures with the population in mind: this was 60 people, mostly men, with an average body mass index just under 30.
ABBV-295 is an investigational long-acting amylin analog, discovered by Gubra using its streaMLine platform and developed by AbbVie. Its mean half-life in phase 1 was 10.7 to 12.3 days, and the companies say that supports dosing intervals beyond weekly. No sequence, residue count or modification has been disclosed. A phase 2 trial in adults with overweight and obesity, NCT07752979, began in August 2026.
What it's used for
Nothing yet. It is an investigational injection for overweight and obesity, in a phase 2 trial that started in August 2026.
How does ABBV-295 work?
What it does in the body, and where.Amylin is released with insulin and tells the brainstem a meal has arrived. Drugs copying it blunt appetite and slow the stomach, and they work alongside the GLP-1 drugs rather than through the same receptor. The engineering problem is duration.
- 01What amylin doesThe natural hormone acts on amylin receptors in the brainstem's appetite centers, slowing stomach emptying and reducing how much food feels necessary. The natural peptide aggregates and clears quickly, and that is why every drug in this class is a modified version rather than the hormone itself.
- 02Where the ten to twelve days comes fromGubra has not said. The release names the discovery platform and the resulting half-life of 10.7 to 12.3 days and publishes no sequence, no residue count and no modification, so the mechanism behind the duration is not public.
- 03Why the monthly arm is the interesting oneWeekly dosing produced 7.8 to 9.8 percent weight loss at 12 weeks. A single 8 mg injection each month produced 7.9 percent at 13 weeks, and every other week produced 9.7 percent. If that holds up in larger trials, the argument for this drug is the injection schedule rather than the depth of the effect.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
What phase 1 actually showed
Investigational- Human trialSixty participants, 45 on ABBV-295 and 15 on placebo, over 12 or 13 weeks. Weight fell 7.8 to 9.8 percent on weekly dosing, 9.7 percent every other week and 7.9 percent monthly, against about 0.3 percent on placebo.
- Human trialMean half-life 10.7 to 12.3 days, the figure that makes a monthly injection arguable at all.
- No dataThe population matters for reading those numbers: mean age 41.5, mean body mass index 29.3 and 88 percent men. That is a dose-finding group at the threshold of obesity, not the population a phase 3 enrolls.
Tolerability, reported in some detail
Investigational- Human trialNausea 33.3 percent against 20.0 percent on placebo, diarrhea 20.0 percent against none. Gastrointestinal events were mostly mild and clustered in the first six weeks, and 92 percent of those affected had mild as their worst event.
- Human trialGastrointestinal discontinuations were 4.4 percent against none on placebo. No severe gastrointestinal events and no serious treatment-emergent adverse events were reported.
- No dataA placebo nausea rate of 20 percent in a 15-person placebo group is three people, so the difference rests on small numbers in both arms.
What has not been disclosed
none- No dataNo sequence, no residue count and no modification. The release names the discovery platform and nothing about the molecule itself.
- RegulatoryNo FDA substance record, International Nonproprietary Name or CAS number was located, so a sample offered under this name cannot be checked against any reference.
- No dataThe phase 2 dose regimen has not been published either, so which of the three intervals the program chose is not yet public.
The weight-loss figures here invite a comparison they cannot support. Seven to ten percent in a phase 1 of 60 people with an average body mass index of 29.3, 88 percent of them men, over 12 or 13 weeks, is not the same kind of number as a phase 3 result in people with obesity over a year or more. The useful finding is the half-life of 10.7 to 12.3 days and the monthly arm it made possible, not the percentage. The tolerability numbers also rest on small groups: a 20 percent placebo nausea rate means three people out of fifteen. Finally, this is one of eleven amylin entries on this site, so a claim that it is the first or only long-acting amylin analog is wrong; what it has is a published monthly dosing result.
The published record
Papers and trials about ABBV-295
Searched: ABBV-295, ABBV295.
Left out: amylin analog (a class term covering eleven separate amylin entries on this site, including cagrilintide and petrelintide); AbbVie (a company name spanning an entire pipeline); Gubra (the discovery partner, whose name returns platform and transaction coverage); long-acting amylin (a descriptor rather than a name, matching several competing molecules).
5 papers tagged human · 0 not reviews or lab · 0 clinical trial publications
4 registered trials · none with posted results
Furthest stage reached: Phase 2, under way
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about ABBV-295
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
10.7 to 12.3 days
How much, and do you cycle it?
The range, and whether you take breaks.No approved dose; phase 1 used 4 to 14 mg, weekly, every other week or monthly in testing. Not established No range
Dosing intervals of a week, two weeks and a month were all tested in phase 1, and no schedule has been settled. The phase 2 regimen has not been published.
How long does it stay in the body?
The half-life, and where the figure comes from.10.7 to 12.3 daysTrial protocol
Mean half-life measured in the phase 1 multiple ascending dose study, reported as 10.7 to 12.3 days, or 257 to 295 hours. The companies say it supports dosing intervals beyond weekly, and the monthly cohort in that study is the test of it.
Source: Gubra press release, phase 1 data presented at EASD 2026
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Nothing to store: it is not sold anywhere.
ABBV-295 has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Any use outside the trial: no product exists and no approved dose has been set
- Anything sold under this name: no sequence has been published, so a vial cannot be checked against a reference
- Reading a phase 1 weight-loss figure as comparable to a phase 3 result for an approved drug
Stop and get help
- Not applicable outside the trial
Common effects
- Nausea in about a third, mostly mild and mostly in the first six weeks
- Decreased appetite, fatigue, headache and diarrhea each above 20 percent
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is ABBV-295 approved?
And where the numbers on this page come from.No. ABBV-295 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- Checked26 October 2026
- DoseNo dose has been established in people.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
Not approved anywhere. Gubra reported detailed phase 1 data on September 30, 2026, presented at EASD 2026. The multiple ascending dose part enrolled 60 participants, 45 on ABBV-295 and 15 on placebo, with a mean age of 41.5, a mean body mass index of 29.3 and 88 percent men, dosed at 4, 6 or 14 mg once weekly, 14 mg every other week or 8 mg monthly for 12 or 13 weeks. A phase 2 trial in adults with overweight and obesity, NCT07752979, was initiated in August 2026. The release states that the safety and efficacy of ABBV-295 have not been established and that it has not been approved by any health regulatory authority worldwide. No FDA substance record, International Nonproprietary Name or CAS number was located.
You can compare this against the whole library, or read how to check a seller.
What else is like ABBV-295?
Others in Amylin analogs, side by side.If you're weighing ABBV-295, it's worth reading Amycretin, ASC36, and AZD6234 in the same class.
The amylin entry where monthly dosing, not the size of the number, is the point.
- Dose
- No approved dose; phase 1 used 4 to 14 mg
- How often
- Weekly, every other week or monthly in testing
An experimental two-in-one weight-loss compound, as a pill or a shot.
- Dose
- 0.3 up to 60 mg per week
- How often
- Once weekly (injected)
An experimental amylin drug from Hong Kong-listed Ascletis, with rat and monkey data only and an undisclosed structure.
- Dose
- No human dose disclosed
- How often
- Monthly injection or daily tablet (intended)
An experimental weekly fullness-hormone shot from AstraZeneca, tuned to the amylin receptor.
- Dose
- Once weekly in trials; milligram dose levels have not been publicly disclosed
- How often
- Weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Gubra press release, detailed phase 1 data for ABBV-295 at EASD 2026(2026)Dated September 30, 2026 and the source of every figure on this page. Describes ABBV-295 as an investigational long-acting amylin analog discovered by Gubra using its streaMLine platform, with no chemical detail beyond that. The multiple ascending dose part enrolled 60 participants, 45 on drug and 15 on placebo, mean age 41.5, mean body mass index 29.3, 88 percent male, at 4, 6 or 14 mg weekly, 14 mg every other week or 8 mg monthly for 12 or 13 weeks. Least-squares mean weight reductions against a placebo of about 0.3 percent were 7.8 to 9.8 percent at week 12 for the weekly cohorts, 9.7 percent at week 13 every other week, and 7.9 percent at week 13 monthly, described as dose-dependent. Mean half-life 10.7 to 12.3 days. Gastrointestinal events mostly mild and mainly in the first six weeks, with 92 percent of those affected having mild as the highest severity; nausea 33.3 against 20.0 percent, diarrhea 20.0 against 0.0 percent, no severe gastrointestinal events, gastrointestinal discontinuations 4.4 against 0.0 percent, and no serious treatment-emergent adverse events. States that safety and efficacy have not been established and that the drug is not approved anywhere. Phase 2, NCT07752979, initiated August 2026.
Beyond these, 5 records are indexed. Browse the records